The content on this site is intended for healthcare professionals only
Dr Kurt Miller from Berlin, Germany, looks ahead in prostate cancer. He reviews the drive for more personalised medicine and reviews biomarkers for partially prognostic and partially predictive markers, such as the composite score of LDH, neutrophil lymphocyte ratio and extent of metastases. He also considers the various genetic markers being explored, such as ERG. He then moves on to talk about potential new compounds, such as cabozantinib, OGX-011, PSMA ADC and bite molecules.
This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson
ASCO GU 2026: Updates in metastatic prostate cancer
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
EAU 2024: Bladder cancer latest
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
